Page 15 - Operations Data News Today

Net earnings were $872.4 million, or $0.85 per diluted share for the first quarter of fiscal 2023 compared with $764.4 million, or $0.71 per diluted share for...

Net earnings were $872.4 million, or $0.85 per diluted share for the first quarter of fiscal 2023 compared with $764.4 million, or $0.71 per diluted share for...

Net earnings were $872.4 million, or $0.85 per diluted share for the first quarter of fiscal 2023 compared with $764.4 million, or $0.71 per diluted share for...

15.08.2022 - Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) reports financial results for the three and six months ended June 30, 2022 and provides a business update. “We are continuing to pursue a potential merger with a ...

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral...

/PRNewswire/ -- U.S. Well Services, Inc. (the "Company," "USWS," "U.S. Well Services" or "we") (NASDAQ: USWS) today reported second quarter 2022 financial and...

/PRNewswire/ -- U.S. Well Services, Inc. (the "Company," "USWS," "U.S. Well Services" or "we") (NASDAQ: USWS) today reported second quarter 2022 financial and...

GuruFocus Article or News written by PurpleRose and the topic is about:

09.08.2022 - Limbach Holdings, Inc. (Nasdaq: LMB) today announced its financial results for the quarter ended June 30, 2022. The company reported consolidated revenue of $116.1 million, which was a decrease of 4.0% compared to the second quarter of 2021. ODR ...

– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing...